NOBOX

NOBOX
Identifiers
Aliases	NOBOX, OG-2, OG2, OG2X, POF5, TCAG_12042, NOBOX oogenesis homeobox
External IDs	OMIM: 610934 MGI: 108011 HomoloGene: 51066 GeneCards: NOBOX
Gene location (Human)
Chr.	Chromosome 7 (human)[1]
End	144,410,227 bp[1]
Gene location (Mouse)
Chr.	Chromosome 6 (mouse)[2]
End	43,309,554 bp[2]
Gene ontology
Molecular function	• DNA binding; • sequence-specific DNA binding; • GO:0001200, GO:0001133, GO:0001201 DNA-binding transcription factor activity, RNA polymerase II-specific;
Cellular component	• cell nucleus;
Biological process	• multicellular organism development; • cell differentiation; • regulation of transcription, DNA-templated; • transcription, DNA-templated; • oogenesis; • regulation of transcription from RNA polymerase II promoter;
	Sources:Amigo / QuickGO
Orthologs
	135935
	18291
	ENSG00000106410; ENSG00000285328
	ENSMUSG00000029736
	O60393
	Q8VIH1
	NM_001080413
	NM_130869
	NP_001073882
	NP_570939
	Wikidata
View/Edit Human	View/Edit Mouse

Homeobox protein NOBOX, also known as newborn ovary homeobox protein, is a protein that in humans is encoded by the NOBOX gene.[5][6][7] The official symbol (NOBOX) and the official full name (NOBOX oogenesis homeobox) are maintained by the HGNC. The NOBOX gene is conserved in chimpanzee, Rhesus monkey, cow, mouse, and rat. There are 175 organisms that have orthologs with human gene NOBOX. It is capable of regulating other genes that are important in the development of follicles. Follicles do not develop and oocytes decrease in its absence which lead to infertility.[8]

Discovery

NOBOX is an in silico subtraction discovery when Suzumori et al. searched for novel genes involved in early mammalian folliculogenesis in 2002. It is one of the several genes that appeared in the search in expressed sequence tag (EST) databases of mouse.[6] It was then cloned and characterised for its genomic structure.

Gene location

The human NOBOX is located in chromosome 7q35 while the mouse NOBOX is in proximal chromosome 6.

Protein structure

The human NOBOX is a 14 kb protein and encoded by 8 exons.[6] It has a proline rich C terminus and contains putative SH3 and WW domains.[9] This C terminus is believed to be critical in its transcriptional activities when bound to oocyte-specific genes.[10] NOBOX belongs to the family of proteins that contains homeodomain. Homeodomain is a stretch of 32 specific amino acids in primates downstream the NOBOX Arg303 residue and is very well-conserved among the species.[11] It contains an asparagine residue at position 51 which is important for its interactions with DNA base pairs.[12][13][14]

Function

NOBOX is a homeobox gene that is preferentially expressed in oocytes. In mice, it is essential for folliculogenesis and regulation of oocyte-specific genes.[7] Regulation of these oocyte-specific genes is thru direct binding of NOBOX to its promoter regions via the specific consensus sequences, the NOBOX DNA binding elements (NBEs). There are three NBEs that have been identified: 5'-TAATTG-3', 5'-TAGTTG-3', and 5'-TAATTA-3'.[10] Knockout study of NOBOX against wild-type ovaries in newborn female mice revealed that 74% (28/38 genes) were downregulated more than 5-fold and 15% (5/33 genes) were upregulated more than 5-fold.[15] However, microRNA population is not affected by NOBOX in newborn ovaries. NOBOX also plays an important role in the suppression of male-determining genes such as Dmrt1.[15] Its deficiency can cause rapid loss of postnatal oocytes and during its absence in female mice, follicles are replaced by fibrous tissue.[6] Recently, a new role of NOBOX in controlling the G2/M arrest was discovered.[16]

Mutations and clinical significance

A mutation in the NOBOX gene is associated with premature ovarian failure (POF), also known as premature ovarian insufficiency (POI).[17] It is a condition which ovaries loss its normal function before the age of 40. It is a heritable disease in up to 30% of patients which is characterised by secondary infertility, amenorrhea, hypoestrogenism, and elevated follicle-stimulating hormone levels in the serum (FSH>40IU/liter).[18][19] It affects ≈1% of women below 40 years old.[20] A study conducted on 96 white women with POF revealed one case of heterozygous mutation in the NOBOX homeodomain, p.Arg355His, in one patient.[17] This mutation was absent in the control population and significantly disrupts the binding of NOBOX to the NBE. Arg355 is critical to DNA binding and is conserved in the homeodomain of the NOBOX from zebrafish to humans. Moreover, its significant negative effect suggests that NOBOX homeodomain may function as a dimer but its rare occurrence suggests a low contribution to POF. Further investigations on POF were conducted on Caucasian, African, Chinese, and Japanese women diagnosed with POF. Several NOBOX loss-of-function mutations were observed in Caucasian and African women accounting to 6.2%, 5.6% and 6.4%.[11][21][22] These results suggest that NOBOX gene is a strong autosomal candidate for POF and its genetic mechanism involves haploinsufficiency. However, these mutations were not found in Chinese and Japanese women making it a less common explanation for POF in the region.[23][24]

The POF syndrome is a highly heterogenous clinical disorder but a recent study showed the first homozygous mutation associated with NOBOX loss-of-function.[16] One patient out of 96 population diagnosed with POF in China was found with one novel homozygous truncating variant in the NOBOX gene. This truncated variant caused a defective transcriptional activation of GDF9, a well-known target of NOBOX, which led to the lost ability of NOBOX to induce G2/M arrest. This finding disagrees that mutation is a less common explanation for POF in Asian population.

Understanding the mutations in NOBOX homeodomain is important to researchers and clinicians to develop diagnostic and therapeutic approaches for POF such as genetic control of mammalian reproductive life-span, regulation of fertility, and generation of mature eggs in the lab.[8]

Interactions

References

ENSG00000285328 GRCh38: Ensembl release 89: ENSG00000106410, ENSG00000285328 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000029736 - Ensembl, May 2017
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: NOBOX oogenesis homeobox".
Suzumori N, Yan C, Matzuk MM, Rajkovic A (February 2002). "Nobox is a homeobox-encoding gene preferentially expressed in primordial and growing oocytes". Mechanisms of Development. 111 (1–2): 137–41. doi:10.1016/S0925-4773(01)00620-7. PMID 11804785. S2CID 7205659.
Huntriss J, Hinkins M, Picton HM (May 2006). "cDNA cloning and expression of the human NOBOX gene in oocytes and ovarian follicles". Molecular Human Reproduction. 12 (5): 283–9. doi:10.1093/molehr/gal035. PMID 16597639.
Rajkovic A, Pangas SA, Ballow D, Suzumori N, Matzuk MM (August 2004). "NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression". Science. 305 (5687): 1157–9. doi:10.1126/science.1099755. PMID 15326356. S2CID 26646489.
Kay BK, Williamson MP, Sudol M (February 2000). "The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains". FASEB Journal. 14 (2): 231–41. doi:10.1096/fasebj.14.2.231. PMID 10657980. S2CID 10475561.
Choi Y, Rajkovic A (November 2006). "Characterization of NOBOX DNA binding specificity and its regulation of Gdf9 and Pou5f1 promoters". The Journal of Biological Chemistry. 281 (47): 35747–56. doi:10.1074/jbc.M604008200. PMID 16997917.
Bouilly J, Bachelot A, Broutin I, Touraine P, Binart N (October 2011). "Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort". Human Mutation. 32 (10): 1108–13. doi:10.1002/humu.21543. PMID 21837770. S2CID 30861702.
Laughon A (December 1991). "DNA binding specificity of homeodomains". Biochemistry. 30 (48): 11357–67. doi:10.1021/bi00112a001. PMID 1742275.
Fraenkel E, Pabo CO (August 1998). "Comparison of X-ray and NMR structures for the Antennapedia homeodomain-DNA complex". Nature Structural Biology. 5 (8): 692–7. doi:10.1038/1382. PMID 9699632. S2CID 24233895.
Kissinger CR, Liu BS, Martin-Blanco E, Kornberg TB, Pabo CO (November 1990). "Crystal structure of an engrailed homeodomain-DNA complex at 2.8 A resolution: a framework for understanding homeodomain-DNA interactions". Cell. 63 (3): 579–90. doi:10.1016/0092-8674(90)90453-l. PMID 1977522. S2CID 1678791.
Choi Y, Qin Y, Berger MF, Ballow DJ, Bulyk ML, Rajkovic A (August 2007). "Microarray analyses of newborn mouse ovaries lacking Nobox". Biology of Reproduction. 77 (2): 312–9. doi:10.1095/biolreprod.107.060459. PMID 17494914.
Li L, Wang B, Zhang W, Chen B, Luo M, Wang J, Wang X, Cao Y, Kee K (January 2017). "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency". Human Reproduction. 32 (1): 248–255. doi:10.1093/humrep/dew271. PMID 27836978.
Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A (September 2007). "NOBOX homeobox mutation causes premature ovarian failure". American Journal of Human Genetics. 81 (3): 576–81. doi:10.1086/519496. PMC 1950834. PMID 17701902.
Vegetti W, Grazia Tibiletti M, Testa G, Alagna F, Castoldi E, Taborelli M, Motta T, Bolis PF, Dalprà L, Crosignani PG (July 1998). "Inheritance in idiopathic premature ovarian failure: analysis of 71 cases". Human Reproduction. 13 (7): 1796–800. doi:10.1093/humrep/13.7.1796. PMID 9740426.
Coulam CB, Adamson SC, Annegers JF (April 1986). "Incidence of premature ovarian failure". Obstetrics and Gynecology. 67 (4): 604–6. PMID 3960433.
De Vos M, Devroey P, Fauser BC (September 2010). "Primary ovarian insufficiency". Lancet. 376 (9744): 911–21. doi:10.1016/S0140-6736(10)60355-8. PMID 20708256. S2CID 19404756.
Bouilly J, Roucher-Boulez F, Gompel A, Bry-Gauillard H, Azibi K, Beldjord C, Dodé C, Bouligand J, Mantel AG, Hécart AC, Delemer B, Young J, Binart N (March 2015). "New NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expression". The Journal of Clinical Endocrinology and Metabolism. 100 (3): 994–1001. doi:10.1210/jc.2014-2761. PMID 25514101.
Bouali N, Francou B, Bouligand J, Lakhal B, Malek I, Kammoun M, Warszawski J, Mougou S, Saad A, Guiochon-Mantel A (May 2016). "NOBOX is a strong autosomal candidate gene in Tunisian patients with primary ovarian insufficiency". Clinical Genetics. 89 (5): 608–13. doi:10.1111/cge.12750. PMID 26848058. S2CID 25656158.
Qin Y, Shi Y, Zhao Y, Carson SA, Simpson JL, Chen ZJ (April 2009). "Mutation analysis of NOBOX homeodomain in Chinese women with premature ovarian failure". Fertility and Sterility. 91 (4 Suppl): 1507–9. doi:10.1016/j.fertnstert.2008.08.020. PMID 18930203.
Zhao XX, Suzumori N, Yamaguchi M, Suzumori K (June 2005). "Mutational analysis of the homeobox region of the human NOBOX gene in Japanese women who exhibit premature ovarian failure". Fertility and Sterility. 83 (6): 1843–4. doi:10.1016/j.fertnstert.2004.12.031. PMID 15950662.
Bayne RA, Kinnell HL, Coutts SM, He J, Childs AJ, Anderson RA (2015-03-19). "GDF9 is transiently expressed in oocytes before follicle formation in the human fetal ovary and is regulated by a novel NOBOX transcript". PLOS ONE. 10 (3): e0119819. doi:10.1371/journal.pone.0119819. PMC 4366263. PMID 25790371.
Bouilly J, Veitia RA, Binart N (April 2014). "NOBOX is a key FOXL2 partner involved in ovarian folliculogenesis". Journal of Molecular Cell Biology. 6 (2): 175–7. doi:10.1093/jmcb/mju006. PMID 24620032. S2CID 16608843.
Bouilly J, Beau I, Barraud S, Bernard V, Delemer B, Young J, Binart N (July 2017). "R-spondin2, a novel target of NOBOX: identification of variants in a cohort of women with primary ovarian insufficiency". Journal of Ovarian Research. 10 (1): 51. doi:10.1186/s13048-017-0345-0. PMC 5526297. PMID 28743298.